308 related articles for article (PubMed ID: 32721437)
21. A 12-Week Maintenance Therapy with a New Prepared Viscous Budesonide in Pediatric Eosinophilic Esophagitis.
Oliva S; Rossetti D; Papoff P; Tiberti A; Mallardo S; Volpe D; Ruggiero C; Russo G; Vezzoli D; Isoldi S; Cucchiara S
Dig Dis Sci; 2019 Jun; 64(6):1571-1578. PubMed ID: 30659470
[TBL] [Abstract][Full Text] [Related]
22. A New Formulation of Oral Viscous Budesonide in Treating Paediatric Eosinophilic Oesophagitis: A Pilot Study.
Oliva S; Rossetti D; Papoff P; Tiberti A; Rossi P; Isoldi S; Amil Dias J; Lucarelli S; Cucchiara S
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):218-224. PubMed ID: 27253660
[TBL] [Abstract][Full Text] [Related]
23. Montelukast Does not Maintain Symptom Remission After Topical Steroid Therapy for Eosinophilic Esophagitis.
Alexander JA; Ravi K; Enders FT; Geno DM; Kryzer LA; Mara KC; Smyrk TC; Katzka DA
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):214-221.e2. PubMed ID: 27650328
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
[TBL] [Abstract][Full Text] [Related]
25. Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.
Dellon ES; Collins MH; Katzka DA; Hudgens S; Lan L; Williams J; Vera-Llonch M; Hirano I
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):699-706.e4. PubMed ID: 32272243
[TBL] [Abstract][Full Text] [Related]
26. Peripheral blood eosinophils and other non-invasive biomarkers can monitor treatment response in eosinophilic oesophagitis.
Schlag C; Miehlke S; Heiseke A; Brockow K; Krug A; von Arnim U; Straumann A; Vieth M; Bussmann C; Mueller R; Greinwald R; Bajbouj M
Aliment Pharmacol Ther; 2015 Nov; 42(9):1122-30. PubMed ID: 26314389
[TBL] [Abstract][Full Text] [Related]
27. Delayed hypersensitivity reaction to orodispersible budesonide in a case with eosinophilic esophagitis.
Andrist CM; Jörg L; Greuter T; Gschwend A; Straumann A; Helbling A
BMC Gastroenterol; 2020 Dec; 20(1):419. PubMed ID: 33308158
[TBL] [Abstract][Full Text] [Related]
28. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
Miehlke S; Madisch A; Kupcinskas L; Petrauskas D; Böhm G; Marks HJ; Neumeyer M; Nathan T; Fernández-Bañares F; Greinwald R; Mohrbacher R; Vieth M; Bonderup OK;
Gastroenterology; 2014 May; 146(5):1222-30.e1-2. PubMed ID: 24440672
[TBL] [Abstract][Full Text] [Related]
29. In eosinophilic esophagitis, budesonide orodispersible tablets maintained remission at 48 wk.
Srinivasan S; Sharma P
Ann Intern Med; 2021 Apr; 174(4):JC44. PubMed ID: 33819066
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.
Gupta SK; Vitanza JM; Collins MH
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):66-76.e3. PubMed ID: 24907502
[TBL] [Abstract][Full Text] [Related]
31. Combined and Alternating Topical Steroids and Food Elimination Diet for the Treatment of Eosinophilic Esophagitis.
Reed CC; Safta AM; Qasem S; Angie Almond M; Dellon ES; Jensen ET
Dig Dis Sci; 2018 Sep; 63(9):2381-2388. PubMed ID: 29380175
[TBL] [Abstract][Full Text] [Related]
32. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
D'Haens GR; Kovács A; Vergauwe P; Nagy F; Molnár T; Bouhnik Y; Weiss W; Brunner H; Lavergne-Slove A; Binelli D; Di Stefano AF; Marteau P
J Crohns Colitis; 2010 Jun; 4(2):153-60. PubMed ID: 21122499
[TBL] [Abstract][Full Text] [Related]
33. Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
Mukkada VA; Gupta SK; Gold BD; Dellon ES; Collins MH; Katzka DA; Falk GW; Williams J; Zhang W; Boules M; Hirano I; Desai NK
J Pediatr Gastroenterol Nutr; 2023 Dec; 77(6):760-768. PubMed ID: 37718471
[TBL] [Abstract][Full Text] [Related]
34. Recent insights on the use of topical steroids in eosinophilic esophagitis.
Reddy A; Ashat D; Murali AR
Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):953-963. PubMed ID: 32567417
[TBL] [Abstract][Full Text] [Related]
35. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence.
Miehlke S; Lucendo AJ; Straumann A; Jan Bredenoord A; Attwood S
Therap Adv Gastroenterol; 2020; 13():1756284820927282. PubMed ID: 32565912
[TBL] [Abstract][Full Text] [Related]
36. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis.
Alexander JA; Jung KW; Arora AS; Enders F; Katzka DA; Kephardt GM; Kita H; Kryzer LA; Romero Y; Smyrk TC; Talley NJ
Clin Gastroenterol Hepatol; 2012 Jul; 10(7):742-749.e1. PubMed ID: 22475741
[TBL] [Abstract][Full Text] [Related]
37. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Hirano I; Collins MH; Assouline-Dayan Y; Evans L; Gupta S; Schoepfer AM; Straumann A; Safroneeva E; Grimm M; Smith H; Tompkins CA; Woo A; Peach R; Frohna P; Gujrathi S; Penenberg DN; Li C; Opiteck GJ; Olson A; Aranda R; Rothenberg ME; Dellon ES;
Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
[TBL] [Abstract][Full Text] [Related]
38. A Network Meta-Analysis of Randomized Controlled Trials on the Treatment of Eosinophilic Esophagitis in Adults and Children.
Rokkas T; Niv Y; Malfertheiner P
J Clin Gastroenterol; 2021 May-Jun 01; 55(5):400-410. PubMed ID: 32398629
[TBL] [Abstract][Full Text] [Related]
39. Budesonide for maintenance of remission in Crohn's disease.
Benchimol EI; Seow CH; Otley AR; Steinhart AH
Cochrane Database Syst Rev; 2009 Jan; (1):CD002913. PubMed ID: 19160212
[TBL] [Abstract][Full Text] [Related]
40. Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis.
Hirano I; Safroneeva E; Roumet MC; Comer GM; Eagle G; Schoepfer A; Falk GW
Aliment Pharmacol Ther; 2020 Apr; 51(8):750-759. PubMed ID: 32149424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
